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Abstract
The multi-protein b-catenin destruction complex tightly regulates b-catenin protein levels by shuttling b-catenin to the
proteasome. Glycogen synthase kinase 3b (GSK3b), a key serine/threonine kinase in the destruction complex, is responsible
for several phosphorylation events that mark b-catenin for ubiquitination and subsequent degradation. Because modulation
of both b-catenin and GSK3b activity may have important implications for treating disease, a complete understanding of the
mechanisms that regulate the b-catenin/GSK3b interaction is warranted. We screened an arrayed lentivirus library
expressing small hairpin RNAs (shRNAs) targeting 5,201 human druggable genes for silencing events that activate a b-
catenin pathway reporter (BAR) in synergy with 6-bromoindirubin-39oxime (BIO), a specific inhibitor of GSK3b. Top screen
hits included shRNAs targeting dihydrofolate reductase (DHFR), the target of the anti-inflammatory compound
methotrexate. Exposure of cells to BIO plus methotrexate resulted in potent synergistic activation of BAR activity,
reduction of b-catenin phosphorylation at GSK3-specific sites, and accumulation of nuclear b-catenin. Furthermore, the
observed synergy correlated with inhibitory phosphorylation of GSK3b and was neutralized upon inhibition of phosphatidyl
inositol 3-kinase (PI3K). Linking these observations to inflammation, we also observed synergistic inhibition of
lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines (TNFa, IL-6, and IL-12), and increased
production of the anti-inflammatory cytokine IL-10 in peripheral blood mononuclear cells exposed to GSK3 inhibitors and
methotrexate. Our data establish DHFR as a novel modulator of b-catenin and GSK3 signaling and raise several implications
for clinical use of combined methotrexate and GSK3 inhibitors as treatment for inflammatory disease.
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Introduction
b-catenin signaling is critical in normal development and adult
physiology. Both hyper- and hypoactivation of this pathway have
been linked to disease [1,2]. b-catenin signaling is tightly regulated
at the level of intracellular protein accumulation by the b-catenin
destruction complex, which consists of glycogen synthase kinase 3b
(GSK3b), casein kinase 1 (CK1), the scaffold protein Axin, and the
tumor suppressor protein adenomatous polyposis coli (APC) [3].
In the absence of pathway activation by WNT ligands or small
molecule inhibitors of GSK3, b-catenin is sequentially phosphor-
ylated by CK1 and GSK3b[4]. Phosphorylated b-catenin is
recognized by b-TrCP, a component of the dedicated E3 ubiquitin
ligase complex, and following ubiquitination, b-catenin is targeted
for rapid degradation by the proteasome [5]. Strong evidence
demonstrates that mutations resulting in constitutive activation of
b-catenin, promote the initiation and progression of colon cancer.
Greater than 80% of colorectal tumors have loss-of-function
mutations in APC and many of the remaining tumors harbor gain-
of-function mutations in b-catenin itself [6,7,8]. While increased b-
catenin signaling drives progression of colon cancer, paradoxically,
hyper-activation of b-catenin may actually promote survival of
melanoma patients by altering melanoma cell fate to a less
proliferative state [9,10]. Several other major human diseases
including mood disorders, Alzheimer disease, and osteoporosis
may involve reduced b-catenin signaling [1]. In the past several
years it has also become clear that GSK3 is a prominent mediator
of inflammation, and it is likely that this function of GSK3
underlies the pathology of several disease states [11,12]. Although
much is now known regarding control of b-catenin and GSK3b
function, to better understand how to therapeutically modulate
this fundamental pathway additional pathway regulators must be
identified.
High-throughput RNA interference (RNAi) screening in
cultured human cells represents a powerful, unbiased, and
comprehensive genetic approach for dissecting the contribution
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use of libraries of chemically synthesized small interfering RNAs
(siRNAs), or small hairpin RNAs (shRNAs) expressed from vectors
and packaged as pseudotyped viral particles, we and others have
shown the utility of RNAi screens to define modulators of clinically
relevant and investigative compounds [13,14,15]. Because the b-
catenin/GSK3 pathway represents a potentially valuable, albeit
complex, target of interest, we performed an RNAi screen to
identify potentially druggable modulators of a GSK3-specific
inhibitor, 6-bromoindirubin-39oxime (BIO). We screened a library
of .13,000 individually arrayed lentiviral shRNA vectors
targeting .5,000 druggable human genes for vectors that would
activate a b-catenin pathway reporter (BAR) [16] synergistically
with a suboptimal dose of BIO. We expect that confirmed hits
from this screen may represent novel targets for therapeutically
manipulating b-catenin/GSK3 signaling and potentially uncover
strategies for combination therapies that may increase the potency
of GSK3-specific inhibitors.
Results
Screening a lentiviral shRNA library targeting the
druggable genome for GSK3 inhibitor enhancers
We screened RKO colon carcinoma cells that express a b-
catenin responsive firefly luciferase reporter (BAR) [16]. Intracel-
lular b-catenin accumulation and subsequent luciferase expression
are tightly regulated in this reporter line by an intact b-catenin
destruction complex. In these cells, inhibition of this complex by a
GSK3-specific inhibitor results in b-catenin accumulation and
translocation to the nucleus and robust luciferase expression. We
optimized this reporter assay to identify shRNAs that synergize
with GSK3 inhibition by establishing a dose of BIO that activates
BAR only in concert with a silencing event that impairs GSK3
activity (Figure 1A). To do this we compared BAR activation in
cells transduced with an shRNA targeting either GSK3b itself or
another gene such as Axin1 that facilitates GSK3 regulation of b-
catenin, to untransduced cells or cells transduced with a lentiviral
vector control. Although none of the vectors tested resulted in
reporter activation in the absence of BIO, cells transduced with
shRNA vectors targeting GSK3b or Axin1 consistently enabled a
sub-optimal, non-activating dose of BIO (312 nM) to activate
BAR luciferase expression compared with vector control and
uninfected cells (Figure 1B). We used this concentration of BIO to
screen for shRNA enhancers of GSK3 inhibitor activity.
Next we screened an arrayed library of 13,609 lentiviral shRNAs,
targeting 5,201 human genes predicted to constitute the druggable
genome [17]. Samples were screened in triplicate, and stringent hit
calling criteria were set at a normalized mean fold-change of greater
than 3 with a Student’s t-test P value less than 0.01 (Figure 1C, and
Table 1). With this data restriction, the screen yielded 12 top hits
(0.09% of the library) that resulted in robust reporter activation in
concert with a non-activating dose of BIO. Consistent with known
biology, these select hits included 6 distinct shRNAs in the library
targeting known members of the b-catenin destruction complex
(two GSK3b shRNAs, two APC shRNAs, one Axin1 shRNA, and
one CK1a shRNA). The remaining top hits were represented by
shRNAs targeting potential novel regulators of GSK3 signaling and
included two distinct shRNAs targeting dihydrofolate reductase
(DHFR), two PSMD7 shRNAs, and single shRNAs targeting ELA2
and RNF10. Reduction of hit-calling criteria stringency (mean fold
change .2.5, P value ,0.05) added third shRNAs targeting
GSK3b and DHFR to this list of BIO enhancers (Supplementary
Table 1).Because, outside of GSK3b, DHFR was the only target on
our hit list represented by three distinct shRNA vectors, and given
that DHFR is the target of the widely used anti-inflammatory drug
methotrexate [18], we focused hit confirmation and follow up
analysis on the potential relationship between DHFR and GSK3.
DHFR shRNA hit confirmation
To confirm DHFR as a hit, we regenerated vectors for all three
library DHFR shRNA sequences, verified them by DNA
sequencing (not shown), and packaged them into lentiviral
particles. As expected, in concert with a sub-optimal dose of
BIO, the DHFR shRNAs induced robust activation of BAR to
levels similar to that induced by shRNAs targeting GSK3b
(Figure 2A). The three DHFR shRNA vectors induced target
knockdown to 34%, 50%, and 21% (DHFR shRNAs 1, 2, and 3,
respectively) of the DHFR mRNA levels in the vector alone (U6-
term) control sample. Correlation between phenotype and
silencing was reasonable given that the vector that induced the
greatest DHFR silencing also resulted in the strongest pathway
activation (DHFR shRNA 3). To strengthen our confidence that
the observed reporter activation resulted from on-target inhibition
of DHFR, we exposed RKO-BAR cells to a titration of
methotrexate in the presence or absence of a suboptimal dose of
BIO. Neither methotrexate nor the suboptimal dose of BIO alone
significantly increased BAR activity. However, when added in
combination, reporter activation increased in a manner dependent
on increasing concentrations of methotrexate (Figure 2B). To-
gether with the observation that three distinct shRNAs targeting
the same gene resulted in the same phenotype, these results
support the conclusion that the observed effect is due to on-target
inhibition of DHFR. In addition, synergistic BAR activation was
also driven by combined exposure of cells to methotrexate and a
second structurally unrelated GSK inhibitor (GSK inhibitor VIII,
Calbiochem), but not by the combination of methotrexate and
lithium or Wnt-3a conditioned medium (Figure 3A). Interestingly
the selectivity of the synergistic interaction correlated with
increased phosphorylation of an inhibitory residue (Ser-9) on
GSK3b induced by BIO or GSK3 inhibitor VIII, but not by
lithium or Wnt-3a (Figure 3B). Importantly, while the enhance-
ment may be selective for certain GSK3 inhibitors, the data
suggest that the capacity to synergize with DHFR inhibition is not
specific to a structural class of GSK3 inhibiting compounds.
DHFR inhibition enhances accumulation of b-catenin
protein by decreasing GSK3-mediated phosphorylation
of b-catenin
To investigate how DHFR inhibition enhanced the effect of
GSK3 inhibition, we tested whether inhibition by shRNA
silencing or methotrexate led to an increase in b-catenin mRNA
and protein levels. To examine these possibilities, we transduced
RKO-BAR cells with DHFR shRNA and control viruses, exposed
cells to BIO or vehicle control, and then measured the
accumulation of b-catenin protein by Western blot and b-catenin
mRNA by Q-PCR. Consistent with an impact on the b-catenin
destruction complex, silencing of DHFR increased b-catenin
protein levels in concert with BIO, but no increase in the transcript
was observed (Figure 4A and Figure S1). This result was confirmed
further by the dose-dependent nuclear accumulation of b-catenin
following exposure of cells to a sub-optimal concentration of BIO
and a titration of methotrexate measured by immunofluorescent
staining with a b-catenin specific antibody and the nuclear dye
Hoechst (Figure 4B and 4C).
DHFR regulates the regeneration of tetrahydrofolate, a carrier
of one-carbon units used in a variety of biosynthetic processes
including synthesis of pyrimidines, S-adenosylmethionine (SAM),
DHFR Modulates b-Catenin/GSK3b
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to cells exposed to methotrexate and GSK3 inhibitor completely
ablated b-catenin accumulation, whereas addition of thymidine
had no effect (Figure 4D). Furthermore, three shRNAs targeting
thymidylate synthetase within our screening library failed to
enhance GSK3-inhibitor driven BAR activation. These observa-
tions are consistent with a role for DHFR in regulating GSK3
activity via synthesis of purines and/or SAM, but not pyrimidines
and suggest that the impact of DHFR inhibition on GSK3 is
unlikely to result from inhibition of DNA synthesis or repair, both
of which require intact thymidine synthesis. Consistent with the
possibility that the enhancement of BIO by DHFR inhibition is
mediated, at least in part, by perturbation of DNA methylation, co
exposure of cells to BIO and the DNMT inhibitor 59-Aza-29-
deoxycytidine resulted in modest (7-fold) but synergistic activation
of BAR (Figure 4E).
Given that addition of SAM blocked methotrexate enhance-
ment of BIO-induced b-catenin protein accumulation, we
questioned whether aberrant methylation may impact expression
of GSK3b or other members of the destruction complex.
Measurement of mRNA levels of Axin1, Axin2, b-TrPC, CK1a,
CUL4b, and GSK3b by Q-PCR revealed no substantial changes
Figure 1. A screen for enhancers of GSK3 inhibitor activity identified shRNAs targeting DHFR among top hits. (A) Schematic of the
screening assay using the BAR reporter. (B) Establishment of the optimal dose of BIO for the enhancer screen using RKO-BAR cells. RKO-BAR cells were
mock infected (No LV-shRNA), or were infected with lentiviral vectors that expressed no shRNA (LV-control) or shRNAs targeting either GSK3b or
Axin1. Forty eight hours after transduction, cells were exposed to a titration of BIO (GSK3i), and luciferase activity was measured after 24 hr of
exposure to drug. Silencing of GSK3b or Axin1 enhanced luciferase activity at doses of BIO that showed no detectable luciferase activity in mock and
control vector infected cells (green box). This optimized dose range of BIO (300–500 nM) was used in our screen and follow up studies. (C) Volcano
plot of the screen using a lentiviral shRNA library targeting the druggable genome. Samples were screened in triplicate in the presence of 312 nM
BIO. shRNA vectors that increased luciferase activity by 3-fold or greater with a P value less than 0.01 are highlighted as top hits. Among this set of
hits, known members of the b-catenin destruction complex (including GSK3b) are colored and labeled in orange, whereas potentially novel GSK3
modulators including the two DHFR shRNAs are colored maroon. The two PSMD7 shRNAs are colored maroon with an orange outline. An expanded
hit list with full statistical analysis is provided in Table S1.
doi:10.1371/journal.pone.0006892.g001
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alone or in combination with BIO compared to controls (Figure
S1). Although we cannot rule out the possibility that DHFR
inhibitor-induced changes in mRNA expression have some impact
on GSK3 regulation, our data strongly indicate that changes in the
transcript levels of GSK3 or other prominent destruction complex
members do not underlie the observed synergy with BIO.
We next examined whether inhibition of DHFR could interfere
with the ability of GSK3 to phosphorylate substrates such as b-
catenin. Because GSK3 regulates b-catenin stability by phosphor-
ylating b-catenin serine and threonine residues (Ser33/37 and
Thr41) we examined whether DHFR inhibition affected this
phosphorylation event. To enable a comparison of the phosphor-
ylation status of b-catenin between cells with active GSK3 versus
potentially inhibited GSK3, b-catenin degradation was blocked in
all samples by treatment with the proteasome inhibitor MG132. In
line with our previous experiments, exposure to methotrexate had
no affect on b-catenin protein levels or phosphorylation status
compared with control cells treated with MG132 alone. In
contrast, treatment of cells with a fully active concentration of BIO
(2.5 mM) completely inhibited GSK3-mediated phosphorylation of
b-catenin (Ser33/37/Thr41) as well as laddering of total b-catenin
on the protein gel, which is suggestive of decreased b-catenin
ubiquitination. Importantly, cells treated with the dose of BIO
used in our screen (312 nM) exhibited only modest decreases in b-
catenin phosphorylation and laddering, and these effects were
significantly enhanced by co-treatment with methotrexate
(Figure 5). Similar to our previous experiments, the enhancement
of BIO by methotrexate was neutralized by addition of adenosine.
Together, these data indicate that DHFR inhibition and
subsequent inhibition of the purine and/or SAM synthesis arms
of the folate metabolism pathway lead to impaired GSK3 activity
and decreased phosphorylation of b-catenin.
Phosphorylation and inactivation of GSK3b occur in response
to growth factor stimulation of receptor tyrosine kinases and
subsequent activation of PI3K signaling. Since enhancement of
GSK3 inhibitor-mediated BAR activation by methotrexate
correlated with increased inhibitory phosphorylation of GSK3b
(Figure 3), we examined whether the observed synergy required
PI3K activity. Consistent with a requirement for PI3K signaling to
mediate the interaction between DHFR and GSK3 inhibitors,
exposure of cells to the PI3K inhibitor wortmannin blocked BAR
activation induced upon coexposure to methotrexate and BIO
(Figure 6, red bars). A similar response was observed upon
exposure of cells to a second PI3K inhibitor, LY294002 (not
shown). Interestingly, the impact of PI3K inhibition was specific to
BAR activation induced by dual inhibition of DHFR and GSK3,
as wortmannin has little impact on BAR activation induced by an
active concentration of BIO (Figure 6, blue bars). Preliminary gene
expression profiling experiments from our laboratory suggest that
methotrexate-induced expression of multiple growth factors and
growth factor receptors could drive activation of PI3K. However
the exact mechanism regarding the interplay between DHFR,
GSK3, and PI3K requires further investigation.
Methotrexate enhances the anti-inflammatory effect of
GSK3 inhibition
GSK3 promotes pro-inflammatory signaling downstream of
Toll-like receptor (TLR) activation, and GSK3-specific inhibitors
have been shown to significantly decrease TLR-mediated
inflammatory responses. Pre-treatment of primary immune cells
with GSK3 inhibitors substantially increases production of the
anti-inflammatory cytokine IL-10 while suppressing production of
pro-inflammatory cytokines including TNFa, IL-6, and IL-12
[11]. Because methotrexate is widely used to treat inflammation-
related disorders such as rheumatoid arthritis, and our data show
that DHFR inhibition increases the potency of GSK3 inhibitors,
we tested whether methotrexate could enhance the anti-inflam-
matory effects of GSK3 inhibition on peripheral blood mononu-
clear cells (PBMCs). To investigate potential synergy, we first
assessed the anti-inflammatory effect of each drug as a single
agent. PBMCs were pre-treated with a titration of either BIO or
methotrexate, prior to TLR activation by LPS stimulation, and
drug concentrations resulting in sub-maximal modulation of LPS-
induced cytokine production were chosen for assessment of
synergy (data not shown). Consistent with the previously observed
capacity of methotrexate to enhance the potency of BIO in RKO
cells, LPS-induced production of pro-inflammatory cytokines was
severely blunted, whereas production of IL-10 was significantly
increased in PBMCs pre-treated with the drug combination
compared with cells pre-treated with either methotrexate or BIO
alone (Figure 7). Importantly the effect of dual inhibition exceeded
Table 1. Top screen hits for shRNA enhancers of BIO induced BAR activity.
Gene symbol Functional notes P value BAR fold change
Axin 1 b-catenin destruction complex 1.2610-4 172.4
APC b-catenin destruction complex 9.7610-4 119.8
GSK3B b-catenin destruction complex 6.6610-4 26.6
PSMD7 26S proteasome, putative regulatory subunit 4.4610-5 19.6
CSNK1A1 b-catenin destruction complex 4.0610-3 19.4
APC b-catenin destruction complex 5.7610-4 16.9
GSK3B b-catenin destruction complex 6.0610-3 14.3
DHFR Folate biosynthesis, target of methotrexate 3.2610-3 10.7
RNF10 ring finger, transcription factor binding protein 1.0610-2 4.8
DHFR Folate biosynthesis, target of methotrexate 6.7610-3 4.2
ELA2 Elastase 2 neutrophil 9.7610-3 3.4
PSMD7 26S proteasome, putative regulatory subunit 5.3610-3 3.4
The gene symbol and functional annotation for each intended shRNA is provided. P value and BAR fold change compared with the median luciferase signal of the
sample field for each screen plate were calculated as described in experimental procedures.
doi:10.1371/journal.pone.0006892.t001
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dual inhibition of DHFR and GSK3 results in a synergistic anti-
inflammatory effect.
Discussion
High-throughput RNAi screening provides an unbiased and
powerful means to interrogate attractive drug targets with complex
signaling functions. Such screens can reveal unexpected interac-
tions that impact mechanisms of target regulation and can
ultimately promote advancement strategies for target-specific
inhibitors in the clinic. A growing body of literature indicates that
positive modulation of b-catenin signaling has potential in the
treatment of a wide range of diseases, and small molecule
inhibitors of GSK3 represent one means to potentiate this
pathway [1]. Moreover, recent evidence has focused on GSK3
as a potential target for treating inflammation-related conditions
[11,12]. Our screen revealed the intriguing observation of synergy
between a GSK3 specific inhibitor, BIO, and shRNA molecules
that silence DHFR, the target of the widely used anti-
inflammatory drug methotrexate. This finding highlights a novel
interaction between folate metabolism and b-catenin/GSK3 signal
transduction pathways and suggests potential opportunities for the
use of DHFR and GSK3 inhibitors in the clinic.
To our knowledge, this is the first report of modulation of GSK3
activity by inhibition of DHFR. However, links between folic acid
intake and b-catenin have been observed previously. Patients with
rectal adenomas treated with dietary folic acid supplementation
for one year exhibited reduced nuclear translocation of b-catenin
and reduced cellular expression of inactive phospho-Ser9-GSK3b
compared with placebo treated controls [20]. Also intriguing is the
finding that the Crooked tail (Cd) model of human folate-
responsive neural tube defects is mutated in Wnt coreceptor Lrp6
[21]. Furthermore, significantly increased levels of b-catenin
protein and nuclear localization were observed upon examination
of the colonic mucosa of mice subjected to combined depletion of
folate and B-vitamins for a period of 10 weeks [22]. This effect was
attributed to DNA hypomethylation and subsequent induction of
strand breaks within the APC gene leading to decreased expression
of APC mRNA. Consistent with this observation, mice expressing
hypomorphic alleles of DNMT1 that result in reduced genomic
methylation, exhibit an increased incidence of APC LOH event
and increase b-catenin accumulation in microadenomas of the
colon [23]. Although we did not observe an obvious effect on APC
expression upon inhibition of DHFR, the results described in the
two aforementioned studies are consistent with our observation
that cellular exposure to SAM, the major donor of one-carbon
units in cellular methylation reactions, blocked the synergistic
accumulation of b-catenin that occurred in response to dual
inhibition of DHFR and GSK3. The lack of effect on APC
expression in our studies may be due to the short duration of our
assays (hours – days) compared with the longer studies performed
in the mouse models and in the clinic (weeks – 1 year). Our data
suggest that early consequences of decreased folate metabolism,
mediated at least in part by decreased cellular methylation, can
lead to a more immediate impact on b-catenin regulation by
GSK3 than indicated previously.
The mechanism of the interaction between DHFR inhibition
and b-catenin/GSK3 is likely to be complex and due to cross-talk
between these signaling pathways rather than direct activation of
GSK3 by DHFR. Although DHFR inhibition increased the
potency of BIO, in the absence of BIO, methotrexate and RNAi-
induced silencing of DHFR had no effect BAR activity, b-catenin
accumulation, or b-catenin phosphorylation. Evidence shown here
suggests that alterations in methylation caused by DHFR
inhibition may underlie the synergy with BIO. However, to what
extent the observed synergy is due to changes in DNA methylation
versus changes in protein methylation, or both, remains to be
determined. The observation that exposure to adenosine blocked
the synergistic effect of combined DHFR and GSK3 inhibition
opens the possibility that signaling events outside of those
perturbed by changes in methylation may play a role in regulating
pathway cross-talk. To date, four key mechanisms have been
identified that contribute to regulation of GSK3. These include
regulation by phosphorylation of GSK3 itself, the subcellular
Figure 2. GSK3 inhibitor activity is enhanced by either DHFR
silencing or inhibition by methotrexate. (A) Hit confirmation by
the BAR assay. Fresh virus generated for DHFR shRNAs, GSK3b shRNAs,
and empty vector controls was used to transduce RKO-BAR cells.
48 hours following transduction cells were exposed to a sub-optimal
(non-activating) dose of GSK3i (312 nM) for another 24 hours before
measuring pathway activation by luciferase activity. Importantly, all
three vectors targeting DHFR (red bars) induced similar levels of
activation as shRNAs targeting GSK3b. (B) Examination of the effect of
the DHFR inhibitor methotrexate on BAR activation by BIO. RKO-BAR
cells were exposed to a titration of methotrexate in the presence (red)
or absence (blue) of a non-activating dose of BIO and luciferase activity
was measured. In confirmation of the enhancement of BIO activity in
cells transduced with shRNA targeting DHFR, inhibition by methotrex-
ate is synergistic with GSK3 inhibition for activation BAR.
doi:10.1371/journal.pone.0006892.g002
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and the phosphorylation status of GSK3 substrates [24]. The data
presented here suggest the possibility that inhibition of folate
metabolism primes cells for GSK3b inhibition and subsequent b-
catenin activation by upregulating activators of PI3K signaling.
Given the recent demonstration of anti-inflammatory properties
of GSK3 inhibitors, and the use of low dose methotrexate as the
gold standard treatment for rheumatoid arthritis, our data raise
several interesting possibilities for the use of these inhibitors in the
clinic. The observation that dual inhibition of GSK3 and DHFR
led to a synergistic anti-inflammatory response suggests that the
combination of DHFR and GSK3 inhibitors may have merit for
use in the clinic. However, it is unclear whether the potent anti-
inflammatory effect of combined inhibition requires activation of
b-catenin signaling. The ability to separate the anti-inflammatory
and pro-oncogenic effects of dual DHFR and GSK3 inhibition will
ultimately determine the utility of the proposed combination
therapy for treatment of chronic inflammatory conditions.
Interestingly, rheumatoid arthritis patients treated with metho-
trexate were found to have a 50% increased risk of developing
certain cancers [25]. Increased b-catenin signaling provides a
plausible molecular mechanism for this increased risk in patients
on methotrexate. While increased b-catenin signaling has clearly
been linked to development of certain cancers such as colon
cancer, two studies in malignant melanoma suggest that elevated
nuclear b-catenin may improve survival [9,10]. It is possible that
depending on the cellular context, b-catenin can promote either
oncogenic proliferation or de-differentiation of tumor cells into a
less pathologic state. In the latter case, agents such as methotrexate
that synergize with b-catenin pathway activators may have a
therapeutic effect in the oncology clinic. Further mechanistic
understanding of the interactions between DHFR, GSK3, and b-
catenin should lead to insights as to how to best modulate GSK3
as a drug target.
Materials and Methods
Reagents
293FT producer cells (Invitrogen, Carlsbad, CA) were main-
tained as per the manufacturer’s specifications in DMEM
supplemented with 10% FBS, and 0.1 mM MEM non-essential
amino acids, 2 mM L-glutamine, 1% Pen/strep, and 500 mg/ml
Geneticin (Invitrogen). HT29 (ATCC, Rockville, MD) and RKO-
BAR cells engineered to express a b-catenin responsive firefly
luciferase reporter (BAR)[16] were maintained in DMEM
supplemented with 10% fetal bovine serum. Primary human
Figure 3. BAR activation induced by dual inhibition of DHFR and GSK3 correlates with increased GSK3b phosphorylation. (A) The
experiment was performed as described for BIO in figure legend 2 with the substitution of an alternative GSK3 inhibitor. (B) RKO-BAR cells were
exposed to multiple activators of b-catenin signaling (GSK3 specific inhibitors BIO and GSK3i VIII, lithium chloride (LiCL), and Wnt3A conditioned
medium (3ACM)) or controls (DMSO, NaCL, and control conditioned medium (LCM)). Protein lysates were harvested and subjected to Western Blot
analysis with a GSK3b phospho-serine 9 specific antibody. The enhancement of BAR activity by DHFR inhibition correlated with agents that induced
phosphorylation of GSK3 at inhibitory residue serine 9. The result is representative of two separate experiments.
doi:10.1371/journal.pone.0006892.g003
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transduced with a lentiviral vector control lacking an shRNA (U6-TERM), with vectors encoding shRNAs targeting b-catenin or GSK3b, or with vectors
encoding three distinct shRNAs targeting DHFR and then exposed to BIO (right lanes) or vehicle control (left lanes) 48 hours following transduction.
Protein lysates were harvested and subjected to Western Blot analysis with a b-catenin specific antibody. Whereas none of the vectors had an effect
in the absence of drug, silencing of GSK3b or DHFR synergized with BIO to induce accumulation of b-catenin (CTNNB1, blot is representative of three
separate experiments). (B) RKO-BAR cells were exposed to methotrexate (MTX), BIO (312 nM), or the combination of the two drugs and stained with
the nuclear dye Hoechst and with an antibody recognizing b-catenin. Images were collected on an InCELL 1000 high content imager. A synergistic
increase in b-catenin expression and nuclear localization was observed upon dual inhibition of GSK3 and DHFR. (C) RKO-BAR cells were exposed to a
titration of methotrexate in the presence of 312 nM BIO and stained for b-catenin. b-catenin expression was quantified on an Acumen Explorer laser
scanning microplate reader. As shown in the graph, a methotrexate dose-dependent increase in b-catenin levels was observed (red curve, each point
represents the average of six replicate samples). The effect of a BAR-activating dose of BIO alone (1 mM) is provided as a reference (blue). (D) RKO-BAR
cells were subjected to DHFR, GSK3 (BIO 312 nM), or dual inhibition in the absence or presence of products of the folate metabolism pathway. b-
catenin accumulation was analyzed as in panel C. Data represent the mean and standard deviation (SD) of 8 replicate wells for each sample. Addition
of purines (adenosine, Ad., or hypoxanthine, Hypo.) or s-adenosylmethionine (SAM), but not thymidine (Thy.) blocked the synergistic effect of dual
inhibition. (E) RKO-BAR cells were subjected to DNMT inhibition (DNMTi) with 59 Aza-29-deoxycytidine (750 nM), BIO (312 nM), or both inhibitors in
combination. Luciferase activity was measured 16 h following drug addition. Data represent the mean6SD of 4 replicate wells for each sample.
doi:10.1371/journal.pone.0006892.g004
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RPMI supplemented with 10% FBS. Several chemical compounds
and antibodies were used in this study: BIO and GSK inhibitor
VIII (Calbiochem, La Jolla, CA); methotrexate, adenosine,
hypoxanthine, thymidine, s-adenosylmethionine, and total b-
catenin antibody (Sigma Aldrich, St. Louis, MO); phospho-b-
catenin (Ser33/37/Thr41) antibody and phospho-GSK3b (Ser-9)
antibody (Cell Signaling Technology). The shRNAs consisting of a
19mer stem with a 9-base hairpin loop were cloned into the
pLentiLox3.7 vector and were designed using standard asymmetry
rules [26]. Virus packaging was achieved with ViraPower
TM
plasmid mix (Invitrogen). The following DHFR shRNA sequences
were used in this study: DHFR1 (59- GTAGACATGGTCTG-
GATAG-39), DHFR2 (59-GACTTTGAAAGTGACACGT-39),
and DHFR3 (59- GGTAAACAGAATCTGGTGA-39).
Virus production and assay for viral titer
Automated high-throughput lentiviral vector production was
performed as described previously [15]. 13, 609 individual shRNA
vectors targeting 5, 201 human genes (typical coverage of 3
shRNAs per gene) were packaged as lentivirus particles. The
pLentilox3.7 vector encodes EGFP, which was used to assess virus
production for each library sample following infection of HT29
colon carcinoma cells, our standard line for establishing lentivirus
titer (Figures S2 and S3).
High-throughput lentivirus-mediated RNAi screen
Infection conditions were optimized for screening in 384-well
format. Robot-assisted lentiviral infection of RKO-BAR cells was
carried out as follows. One set of 180 96-well infection-ready plates
(IRPs) comprising the screening library was thawed on ice and
kept at 4uC prior to infection. 384-well screening plates were
primed for infection by addition of 15 ml of plating medium
(DMEM, 10% FBS, 25 mM HEPES, Pen/Strep) to each well with
a WellMateH bulk dispensing apparatus (Matrix Technologies,
Hudson, NH). Next, four IRPs were then transferred (10 mlo f
virus/well) into each screening plate in triplicate by use of a
BiomekH FX Laboratory Automation Workstation (Beckman
Coulter, Fullerton, CA). RKO-BAR cells were harvested by
trypsinization and reverse transduced by seeding of the virus-
Figure 5. Methotrexate enhances BIO-mediated inhibition of
phosphorylation at GSK3-specific residues (Ser33/37/Thr41) on
b-catenin. RKO-BAR cells were treated with the proteasome inhibitor
MG132 alone (1 mM), or in combination with other compounds as
depicted, and subjected to immunoprecipitation with a b-catenin
specific antibody followed by Western blot for total and phospho-
(Ser33/37/Thr41) b-catenin. Exposure of cells to suboptimal BIO
(312 nM) plus methotrexate (312 nM) led to a greater decrease in
phosphorylated b-catenin than exposure to the same dose of BIO alone
(compare lanes 4 and 5). As observed with b-catenin accumulation
(Figure 2), further exposure to adenosine (100 mM) neutralized the
impact of methotrexate on BIO-mediated inhibition of b-catenin
phosphorylation. The dashed line denotes that the adenosine treated
sample is from a separate part of the same blot. This result is
representative of three separate experiments.
doi:10.1371/journal.pone.0006892.g005
Figure 6. Methotrexate enhancement of BIO-mediated BAR activation is blocked by the PI3K inhibitor Wortmannin. RKO-BAR cells
treated with either suboptimal BIO (312 nM) plus methotrexate (red bars), or with an active concentration of BIO (1.5 mM, blue bars), were exposed to
a titration of Wortmannin, and luciferase activity was measured 24 h following exposure to drug. Consistent with a requirement for PI3K signaling to
mediate the synergistic interaction between DHFR and GSK3 inhibitors, wortmannin significantly reduced BAR activity induced by the combination of
the two inhibitors in a dose dependent manner. In contrast wortmannin had modest effect on BAR activity induced by the active dose of BIO alone.
Results represent the mean6SD of three replicate wells for each sample.
doi:10.1371/journal.pone.0006892.g006
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presence of 6 mg/ml polybrene in a final volume of 35 mlo f
growth medium using the bulk dispenser. Forty-eight hours after
infection, BIO was added to a final concentration of 312 nM and
firefly luciferase was measured by use of a BriteLite luciferase assay
(PerkinElmer, Waltham, MA) 24 hours later.
Statistical analysis
Smoothing methods were used to adjust for positional effects
including systematic edge effects [27,28]. In each plate, the
difference between the adjusted intensity of an shRNA and the
median in the sample field was calculated [29]. For all shRNA
replicates, these values were used to calculate mean difference
(equivalent to mean fold change in log scale), strictly standardized
mean difference (SSMD) and P value of testing no mean difference
[30,31,32]. The P values were then used to calculate the false
discovery rate (FDR) by use of methods described by Strimmer
[33].
Quantitative PCR
mRNA silencing was quantified by real-time PCR with an ABI
PRISM 7900HT Sequence Detection System and Assays-on-
Demand
TM gene expression products as described previously [13].
The following Assays-on-Demand
TM reagents were used in this study:
DHFR (Hs00758822_s1), GSK3b (Hs00275656_m1), b-catenin
(Hs00170025_m1), Axin1 (Hs00394718_m1), APC
(Hs00181051_m1), Axin2 (Hs00610344), bTrPC (Hs00182707_m1),
Cul4B (Hs00186086_m1), CK1a (Hs00793391_m1).
Measurement of cytokines. Human IL-6, IL-10, and
TNFa in culture supernatants were measured with enzyme-
linked immunosorbent assay (ELISA) kits from Invitrogen. IL-12
was measured with an ELISA kit from Pierce, Rockford, IL.
Supporting Information
Figure S1 DHFR inhibition does not decrease mRNA expres-
sion of known components of the b-catenin destruction complex.
RKO-BAR cells were transduced with DHFR shRNAs or were
exposed to methotrexate with or without BIO and RNA was
harvested for Q-PCR analysis with probes specific for Axin1,
Axin2, b-TRPC, CK1a, CUL4b, and GSK3b. Of the genes
tested, a modest, albeit consistent, reduction in Axin2 expression
alone was observed upon silencing and methotrexate inhibition of
DHFR. However, as expected with activation of b-catenin,
exposure to the combination of BIO and methotrexate led to an
increase in Axin2 expression, and Axin2 shRNAs did not lead to
GSK3 inhibitor enhancement in our screen. It is therefore unlikely
that a reduction in Axin2 levels alone underlies the synergistic
interaction between DHFR and GSK3 inhibitors.
Found at: doi:10.1371/journal.pone.0006892.s001 (0.04 MB
DOC)
Figure 7. DHFR inhibition enhances pro and anti-inflammatory cytokine production by inhibition of GSK3. Cytokine production in
PBMCs preincubated for 1 hr in medium only (No Drug), 5 nM BIO (GSK3i), 10 nM methotrexate (MTX), or the combination of the two compounds
(BIO + MTX) and then stimulated with 300 ng/ml LPS for 20 hr. No LPS controls are shown on the far right of each graph for reference. Cell free
supernatants were analyzed by ELISA for production of TNFa (A), IL-6 (B), IL-12 (C), or IL-10 (D). *, P,0.05, **, P,0.01, and ***, P,0.001, compared
with LPS alone. Results represent the mean6SD of 6 replicate wells for each sample. The results shown are representative of three separate
experiments.
doi:10.1371/journal.pone.0006892.g007
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required to detect enhancement of BIO-mediated activation of
BAR by GSK3b shRNA. Because it is difficult to normalize viral
titers across a large collection of packaged vectors we established a
minimal titer threshold that would be expected to result in BAR
activation if gene silencing enhanced BIO potency. To establish a
minimum effective titer, we exposed HT29 cells to serially diluted
control virus (U6-TERM, which contains the U6 promoter and
two tandem RNA-polymerase III termination sequences but no
shRNA) or virus targeting GSK3b. GFP expression was measured
96 h post transduction to determine titer values in terms of
fluorescent light units on an Acumen Explorer laser scanning
microplate reader (TTP LabTech, Cambridge U.K.). In parallel
with the HT29 infections, RKO-BAR cells were infected with
same serially diluted control virus or lentiviral shRNA targeting
GSK3b. Forty eight hours after infection, cells were exposed to
BIO at a concentration (312 nM) that induces luciferase-based
luminescence only upon infection with an shRNA capable of
negatively modulating GSK3 function. Significance of enhanced
activation of luciferase by the GSK3b shRNA infected cells over
that observed in control vector infected cells is plotted on the Y-
axis. GFP values as Log total intensity fluorescent units as a
measurement of viral titer is plotted on the X-axis. Each data point
represents the comparison of 4 replicate wells for each dilution of
U6-TERM to GSK3b shRNA vector. As expected, we observed a
strong correlation between titer of GSK3b shRNA virus and
enhancement of luciferase activation by BIO. The arrow denotes
the titer value in GFP units (1.76107 FLU) required for 5-fold
enhancement of luciferase activation with a P value of 1610-4. We
set this as our minimal titer value for effective lentiviral shRNA
production for this screen.
Found at: doi:10.1371/journal.pone.0006892.s002 (0.03 MB
DOC)
Figure S3 Analysis of titer values for the lentiviral shRNA
screening library. Titer values were established based on GFP
expression as described in Figure S2. On the basis of the minimal
effective titer values established (described in Figure S1, red line),
all but 77 of our library wells (99.5%) met levels required to enable
enhancement of BIO in our assay assuming efficacy of shRNA-
induced target silencing and impact of GSK3 function. Each green
dot represents an individually produced and analyzed virus. The
entire library was analyzed by use of this method. The bottom
panel is an enlargement of the section encompassed by the blue
box in the top graph.
Found at: doi:10.1371/journal.pone.0006892.s003 (0.07 MB
DOC)
Table S1 Statistical analysis of top shRNA screen hits. Gene
Symbol and ID numbers for the intended targets of each shRNA
screen hit are provided. Hits are ranked by strictly standardized
mean difference (SSMD) using a cut-off of SSMD .1.6. All
statistical metrics were calculated as described in procedures. Each
hit listed represents a distinct shRNA sequence and the three
DHFR shRNA vectors are highlighted in bold.
Found at: doi:10.1371/journal.pone.0006892.s004 (0.03 MB
DOC)
Author Contributions
Conceived and designed the experiments: RAK JF JDB BSR WTA RM
MC. Performed the experiments: RAK JF JA JDB BSR RL. Analyzed the
data: RAK JF JA JDB BSR XDZ MF. Contributed reagents/materials/
analysis tools: RM. Wrote the paper: RAK MC.
References
1. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin
signalling: diseases and therapies. Nat Rev Genet 5: 691–701.
2. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell
127: 469–80.
3. Kimelman D, Xu W (2006) beta-catenin destruction complex: insights and
questions from a structural perspective. Oncogene 25: 7482–91.
4. Liu C, Li Y, Semenov M, Han C, Baeg GH, et al. (2002) Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837–47.
5. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) beta-catenin is a
target for the ubiquitin-proteasome pathway. Embo J 16: 3797–804.
6. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, et al. (1991)
Identification and characterization of the familial adenomatous polyposis coli
gene. Cell 66: 589–600.
7. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, et al. (1991)
Identification of FAP locus genes from chromosome 5q21. Science 253: 661–5.
8. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: Wnt
signaling in cancer. Biochim Biophys Acta 1653: 1–24.
9. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA (2005)
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of
melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:
8606–14.
10. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, et al.
(2009) Activated Wnt/beta-catenin signaling in melanoma is associated with
decreased proliferation in patient tumors and a murine melanoma model. Proc
Natl Acad Sci U S A 106: 1193–8.
11. Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated
cytokine production is differentially regulated by glycogen synthase kinase 3. Nat
Immunol 6: 777–84.
12. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3):
inflammation, diseases, and therapeutics. Neurochem Res 32: 577–95.
13. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, et al. (2006) Small
interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells
having both BRCA network and TP53 disruptions. Mol Cell Biol 26: 9377–86.
14. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007)
A functional genetic approach identifies the PI3K pathway as a major
determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:
395–402.
15. Klinghoffer RA, Roberts B, Annis J, Frazier J, Lewis P, et al. (2008) An
optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-
5 inhibitor sensitivity. Assay Drug Dev Technol 6: 105–19.
16. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, et al. (2007) Wilms
tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
Science 316: 1043–6.
17. Orth AP, Batalov S, Perrone M, Chanda SK (2004) The promise of genomics to
identify novel therapeutic targets. Expert Opin Ther Targets 8: 587–96.
18. Cronstein BN (1992) Molecular mechanism of methotrexate action in
inflammation. Inflammation 16: 411–23.
19. Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, et al. (1984) The
functional human dihydrofolate reductase gene. J Biol Chem 259: 3933–43.
20. Jaszewski R, Millar B, Hatfield JS, Nogothu K, Finkenauer R, et al. (2004) Folic
acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of
patients with colorectal adenomas. Cancer Lett 206: 27–33.
21. Carter M, Chen X, Slowinska B, Minnerath S, Glickstein S, et al. (2005)
Crooked tail (Cd) model of human folate-responsive neural tube defects is
mutated in Wnt coreceptor lipoprotein receptor-related protein 6. Proc Natl
Acad Sci U S A 102: 12843–8.
22. Liu Z, Choi SW, Crott JW, Keyes MK, Jang H, et al. (2007) Mild depletion of
dietary folate combined with other B vitamins alters multiple components of the
Wnt pathway in mouse colon. J Nutr 137: 2701–8.
23. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, et al. (2005)
Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis.
Proc Natl Acad Sci U S A 102: 13580–5.
24. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase
kinase-3. Trends Biochem Sci 29: 95–102.
25. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, et al. (2008)
Incidence of melanoma and other malignancies among rheumatoid arthritis
patients treated with methotrexate. Arthritis Rheum 59: 794–9.
26. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, et al. (2003) A
lentivirus-based system to functionally silence genes in primary mammalian cells,
stem cells and transgenic mice by RNA interference. Nat Genet 33: 401–6.
27. Zhang XD, Espeseth AS, Johnson EN, Chin J, Gates A, et al. (2008) Integrating
experimental and analytic approaches to improve data quality in genome-wide
RNAi screens. J Biomol Screen 13: 378–89.
28. Zhang XD (2008) Novel analytic criteria and effective plate designs for quality
control in genome-scale RNAi screens. J Biomol Screen 13: 363–77.
29. Zhang XD, Yang XC, Chung N, Gates A, Stec E, et al. (2006) Robust statistical
methods for hit selection in RNA interference high-throughput screening
experiments. Pharmacogenomics 7: 299–309.
30. Zhang XD, Ferrer M, Espeseth AS, Marine SD, Stec EM, et al. (2007) The use
of strictly standardized mean difference for hit selection in primary RNA
DHFR Modulates b-Catenin/GSK3b
PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e6892interference high-throughput screening experiments. J Biomol Screen 12:
497–509.
31. Zhang XD (2007) A new method with flexible and balanced control of false
negatives and false positives for hit selection in RNA interference high-
throughput screening assays. J Biomol Screen 12: 645–55.
32. Zhang XD, Heyse JF (2009) Determination of sample size in genome-scale
RNAi screens. Bioinformatics 25: 841–4.
33. Strimmer K (2008) A unified approach to false discovery rate estimation. BMC
Bioinformatics 9: 303.
DHFR Modulates b-Catenin/GSK3b
PLoS ONE | www.plosone.org 11 September 2009 | Volume 4 | Issue 9 | e6892